These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25053452)

  • 1. UNGASS 2016 on drugs, the first challenge for HIV advocates in the post-2015 era.
    Fordham A; Tinasti K
    J Int AIDS Soc; 2014; 17(1):19274. PubMed ID: 25053452
    [No Abstract]   [Full Text] [Related]  

  • 2. Discrimination, HIV among People Who Use Drugs, and the UNGASS 2016 on the World Drug Problem.
    Tinasti K; Ravishankar S; Zuniga JM
    J Int Assoc Provid AIDS Care; 2016 Jul; 15(4):273-5. PubMed ID: 27385648
    [No Abstract]   [Full Text] [Related]  

  • 3. UNGASS: time to put HIV at the forefront of drug policy.
    Lancet HIV; 2016 Apr; 3(4):e147. PubMed ID: 27036984
    [No Abstract]   [Full Text] [Related]  

  • 4. Australia. First, do harm reduction.
    Science; 2014 Jul; 345(6193):156-8. PubMed ID: 25013058
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV and drugs: a common, common-sense agenda for 2016.
    Buse K; Albers E; Phurailatpam S
    Lancet Glob Health; 2016 May; 4(5):e292-3. PubMed ID: 27080461
    [No Abstract]   [Full Text] [Related]  

  • 6. Is there a gender gap in the HIV response? Evaluating national HIV responses from the United Nations General Assembly Special Session on HIV/AIDS country reports.
    Carael M; Marais H; Polsky J; Mendoza A
    J Acquir Immune Defic Syndr; 2009 Dec; 52 Suppl 2():S111-8. PubMed ID: 19901623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHO status paper on prisons, drugs and harm reduction.
    Euro Surveill; 2005 Jul; 10(7):E050714.5. PubMed ID: 16785661
    [No Abstract]   [Full Text] [Related]  

  • 8. Are we on course for reporting on the Millennium Development Goals in 2015?
    Rugg D; Marais H; Carael M; De Lay P; Warner-Smith M
    J Acquir Immune Defic Syndr; 2009 Dec; 52 Suppl 2():S69-76. PubMed ID: 19901629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in global blood safety for HIV.
    Takei T; Amin NA; Schmid G; Dhingra-Kumar N; Rugg D
    J Acquir Immune Defic Syndr; 2009 Dec; 52 Suppl 2():S127-31. PubMed ID: 19901625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing integrated community-based HIV prevention, harm reduction, and sexual and reproductive health services for women who inject drugs.
    Ayon S; Jeneby F; Hamid F; Badhrus A; Abdulrahman T; Mburu G
    Reprod Health; 2019 May; 16(Suppl 1):59. PubMed ID: 31138238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vietnam moves forward with harm reduction: an assessment of progress.
    Reid G; Higgs P
    Glob Public Health; 2011; 6(2):168-80. PubMed ID: 20155544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV and AIDS among adolescents who use drugs: opportunities for drug policy reform within the sustainable development agenda.
    Tinasti K
    J Int AIDS Soc; 2018 Feb; 21 Suppl 1(Suppl Suppl 1):. PubMed ID: 29485748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "We don't need services. We have no problems": exploring the experiences of young people who inject drugs in accessing harm reduction services.
    Krug A; Hildebrand M; Sun N
    J Int AIDS Soc; 2015; 18(2 Suppl 1):19442. PubMed ID: 25724510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    Springer SA; Barocas JA; Wurcel A; Nijhawan A; Thakarar K; Lynfield R; Hurley H; Snowden J; Thornton A; Del Rio C
    J Infect Dis; 2020 Sep; 222(Suppl 5):S230-S238. PubMed ID: 32877568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The UK HIV/AIDS control: inappropriate measures for home and abroad.
    Choudhury CR
    Natl Med J India; 2004; 17(5):283-4. PubMed ID: 15638321
    [No Abstract]   [Full Text] [Related]  

  • 16. Global Fund investments in harm reduction from 2002 to 2009.
    Bridge J; Hunter BM; Atun R; Lazarus JV
    Int J Drug Policy; 2012 Jul; 23(4):279-85. PubMed ID: 22421551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The U.N. system issues calls to strengthen harm reduction interventions.
    HIV AIDS Policy Law Rev; 2009 Dec; 14(2):31-2. PubMed ID: 20225514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the level of HIV prevention coverage, knowledge and protective behavior among injecting drug users: what does the 2008 UNGASS reporting round tell us?
    Mathers BM; Degenhardt L; Adam P; Toskin I; Nashkhoev M; Lyerla R; Rugg D
    J Acquir Immune Defic Syndr; 2009 Dec; 52 Suppl 2():S132-42. PubMed ID: 19901626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the 2001 Declaration of Commitment on HIV/AIDS.
    Warner-Smith M; Rugg D; Frescura L; Moussavi S
    J Acquir Immune Defic Syndr; 2009 Dec; 52 Suppl 2():S77-86. PubMed ID: 19901630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Political rationale, aims, and outcomes of health-related high-level meetings and special sessions at the UN General Assembly: A policy research observational study.
    Rodi P; Obermeyer W; Pablos-Mendez A; Gori A; Raviglione MC
    PLoS Med; 2022 Jan; 19(1):e1003873. PubMed ID: 35025880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.